Clinical trials: HIV Viremia
HIV/AIDS
"Switch Either Near Suppression Or THOusand"
This trial addresses the question of the viral load (VL) threshold for switching from first-line to second-line antiretroviral therapy (ART). The WHO currently sets the threshold at 1000 copies/mL.
- Trial name
- SESOTHO (NCT03088241)
- Testing
- switch
- Where
- 8 sites in Lesotho
- Volunteers
- 80 people
- Sponsor
- Niklaus Labhardt
HIV Infections
Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients
The purpose of this study is to see: (1) how the amount of HIV in the lungs compares to that in the blood; (2) if HAART reduces the amount of HIV in the lungs; and (3) if HAART reduces lung inflammation in HIV-infected patients.
- Trial name
- NCT00001110
- Testing
- Bronchoalveolar lavage
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Effectiveness of Interleukin-2 (IL-2) Plus Anti-HIV Therapy in HIV-Positive Patients
The purpose of this study is to find out if the immune systems of HIV-positive patients can be improved by treatment with anti-HIV medications plus interleukin-2 (IL-2) in the early stages of HIV infection.
- Trial name
- NCT00001131
- Testing
- Aldesleukin, HAART
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Raltegravir Intensification in HIV-infected Patients
The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
- Trial name
- NCT00631449
- Testing
- Raltegravir
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
HIV Infections
Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs
The purpose of this study is to determine whether therapeutic HIV vaccines can help the immune system control HIV viral load after anti-HIV drugs are discontinued.
- Trial name
- NCT00050063
- Testing
- Therapeutic vaccinations from A5058s
- Where
- 14 sites in United States
- Volunteers
- 78 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor Therapy
The purpose of the study is to look at possible reasons why some HIV positive people who take their drugs properly and have no resistance to these drugs, still have low amounts of virus detectable in their blood.
- Trial name
- NCT02354209
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- St Stephens Aids Trust
HIV - Human Immunodeficiency Virus
Improving Management of Recipients of Care With HIV Viremia to Optimize Viral Suppression in Zambia: A Process and Outcome Evaluation
The Centre for Infectious Disease Research in Zambia (CIDRZ) as an implementing partner (IP) through its Centers for Disease Control and Prevention (CDC) and President's Emergency Plan for AIDS Relief (PEPFAR)-funded programs…
- Trial name
- NCT07747987
- Testing
- additional support
- Where
- Zambia
- Volunteers
- 548 people
- Sponsor
- Centre for Infectious Disease Research in Zambia
HIV
Study to Compare the Virologic Efficacy in Cerebrospinal Fluid (CSF) and Neurocognitive State in Patients Infected by HIV-1 Long-term Treatment (> 3 Years) With Lopinavir / Ritonavir Monotherapy
The aim of this study is to describe and compare the percentage of patients infected by HIV-1 to maintain a complete virology suppression at the CSF (CSF CV 1 copy / mL) in patients with CV <50 copies / mL and treated with stable…
- Trial name
- NCT01116817
- Testing
- Lumbar puncture (Lopinavir/ritonavir monotherapy), Lumbar puncture (HAART: Lopinavir/ritonavir + 2 NRTI)
- Where
- Spain
- Volunteers
- 35 people
- Sponsor
- Germans Trias i Pujol Hospital
Cytomegalovirus (CMV) Infection
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse
The goal of this clinical trial is to learn if valganciclovir works to treat cytomegalovirus (CMV) infection in people with advanced HIV disease.
- Trial name
- NIRVANA (NCT07379203)
- Testing
- Valganciclovir
- Volunteers
- 130 people
- Sponsor
- Wits Health Consortium (Pty) Ltd
HIV
Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone
The purpose of this study is to determine the proportion of subjects with HIV-1 RNA < 50 c/mL at Week 48 in patients who failed their first line therapy containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) or an…
- Trial name
- SUPPRESS (NCT01605084)
- Testing
- Atazanavir, Darunavir, Ritonavir
- Where
- 14 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Antiretroviral Therapy (ART) Adherence, PMTCT
Optimizing Prevention and Care for Pregnant and Postpartum Adolescent Girls and Young Women With HIV in Tanzania
The goal of this clinical trial is to find better ways to care for pregnant and postpartum adolescent girls and young women (AGYW) aged 15-24 years with HIV in Tanzania, and to prevent them from passing HIV to their babies.
- Conditions
- HIV Antiretroviral Therapy (ART) Adherence, PMTCT, Pregnancy, Retention in Care
- Trial name
- ENGAGE (NCT06605053)
- Testing
- Co-produced intervention to optimize PMTCT care engagement
- Where
- 2 sites in Tanzania
- Volunteers
- 222 people
- Sponsor
- Karolinska Institutet